Prognostic significance of preoperative and follow-up neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with non-metastatic clear cell renal cell carcinoma

다국어 초록 (Multilingual Abstract)

Purpose: To evaluate the significance of preoperative and follow-up neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic factors for recurrence in patients with non-metastatic clear cell renal cell carcinoma (NMCCRCC).
Materials and Methods: We retrospectively reviewed the medical records of 309 patients with NMCCRCC who underwent radical or partial nephrectomy. The prognostic significance of various clinicopathological variables, preoperative NLR (pNLR) and PLR (pPLR), and NLR and PLR at recurrence or quasi-recurrence (rNLR and rPLR) for recurrence-free survival (RFS) was analyzed.
Results: At mean follow-up of 93 months, 44 patients (14.2%) developed recurrence. In the univariate analysis, clinical presentation, tumor size, pathologic tumor stage, Fuhrman grade, pNLR, pPLR and rNLR were significant prognostic factors for RFS. In the multivariate analysis using pNLR and pPLR as continuous variables, tumor size, pathologic tumor stage and pPLR were independent prognostic factors for RFS. In the multivariate analysis using pNLR and pPLR as dichotomous variables, tumor size, pathologic tumor stage, Fuhrman grade and pNLR ≥1.7 were independent prognostic factors for RFS. In multivariate analyses using rNLR and rPLR, only tumor size and pathologic tumor stage were independent prognostic factors for RFS. In a subset of patients with recurrence or at least 42 months follow-up without recurrence, rNLR ≥1.9 was significantly associated with worse RFS, albeit without independent significance.
Conclusions: pNLR and pPLR are independent prognostic factors for RFS in patients with NMCCRCC. We propose that postoperative follow-up NLR of 1.9 and higher with one or more adverse clinicopathological factors should prompt radiologic evaluation for possible metastasis.

참고문헌 (Reference)

1 Pichler M, "Validation of the pre-treatment neutrophillymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients" 108 : 901-907, 2013

2 Lipworth L, "The epidemiology of renal cell carcinoma" 176 : 2353-2358, 2006

3 Janzen NK, "Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease" 30 : 843-852, 2003

4 Pichler M, "Renal cell carcinoma stage migration in a single European centre over 25 years : effects on 5-and 10-year metastasis-free survival" 44 : 997-1004, 2012

5 Eggener SE, "Renal cell carcinoma recurrence after nephrectomy for localized disease : predicting survival from time of recurrence" 24 : 3101-3106, 2006

6 Byun SS, "Prognostic significance of preoperative neutrophil-tolymphocyte ratio in nonmetastatic renal cell carcinoma : a large, multicenter cohort analysis" 2016 : 5634148-, 2016

7 de Martino M, "Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma" 190 : 1999-2004, 2013

8 Ohno Y, "Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma" 184 : 873-878, 2010

9 Huang J, "Preoperative neutrophil-to-lymphocyte ratio and neutrophilia are independent predictors of recurrence in patients with localized papillary renal cell carcinoma" 2015 : 891045-, 2015

10 Viers BR, "Preoperative neutrophil-lymphocyte ratio predicts death among patients with localized clear cell renal carcinoma undergoing nephrectomy" 32 : 1277-1284, 2014

11 Wen RM, "Preoperative neutrophil to lymphocyte ratio as a prognostic factor in patients with non-metastatic renal cell carcinoma" 16 : 3703-3708, 2015

12 Wojtukiewicz MZ, "Platelets and cancer angiogenesis nexus" 36 : 249-262, 2017

13 Semeniuk-Wojtaś A, "Neutrophil-to-lymphocyte ratio, platelet-tolymphocyte ratio, and C-reactive protein as new and simple prognostic factors in patients with metastatic renal cell cancer treated with tyrosine kinase inhibitors : a systemic review and meta-analysis" 16 : e685-93, 2018

14 Grivennikov SI, "Immunity, inflammation, and cancer" 140 : 883-899, 2010

15 Ohno Y, "Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma" 187 : 411-417, 2012

16 Ferlay J, "Estimates of worldwide burden of cancer in 2008 : GLOBOCAN 2008" 127 : 2893-2917, 2010

17 Kemal Y, "Elevated serum neutrophil to lymphocyte and platelet to lymphocyte ratios could be useful in lung cancer diagnosis" 15 : 2651-2654, 2014

18 Lucca I, "Comparison of the prognostic value of pretreatment measurements of systemic inflammatory response in patients undergoing curative resection of clear cell renal cell carcinoma" 33 : 2045-2052, 2015

19 Mantovani A, "Cancer-related inflammation" 454 : 436-444, 2008

20 Kaynar M, "Bladder cancer invasion predictability based on preoperative neutrophil-lymphocyte ratio" 35 : 6601-6605, 2014

21 Lorente D, "Baseline neutrophil-lymphocyte ratio(NLR)is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use" 26 : 750-755, 2015